• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Provenge (sipuleucel-T)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Provenge (sipuleucel-T)

  • Profile

Profile

Contact Information

Contact: Dendreon Pharmaceuticals
Website: http://www.provenge.com/

Currently Enrolling Trials

    Show More

    General Information

    Dendreon is an autologous cellular immunotherapy designed to induce an immune response targeted against PAP (prostatic acid phosphatase), an antigen expressed in most prostate cancers.

    Provenge is specifically indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

    Mechanism of Action

    Dendreon is an autologous cellular immunotherapy. While the precise mechanism of action is unknown, Provenge is designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers.

    Side Effects

    Adverse events associated with the use of Provenge may include, but are not limited to, the following:

    • Chills
    • Fatigue
    • Fever
    • Back pain
    • Nausea
    • Joint ache
    • Headache

    Dosing/Administration

    Provenge is supplied as an infusion, containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, designed for intravenous administration. The recommended course of therapy is three complete doses, given at approximately two-week intervals.

    Clinical Trial Results

    FDA Approval
    The FDA approval of Provenge was based on three studies.
     

    Study One
    This randomized, double-blind, placebo-controlled, multicenter trial enrolled 512 subjects with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The median overall survival was 25.8 months for the Provenge arm and 21.7 months for the placebo arm (p=0.032).
     

    Studies Two and Three
    These were similar randomized, double-blind, placebo-controlled, multicenter trials in patients with metastatic castrate resistant prostate cancer and no cancer-related pain. The primary end point was time to disease progression; analysis of the primary end point did not reach statistical significance. The median overall survival was 25.9 months for the Provenge arm and 21.4 months for the placebo arm.

    Approval Date: 2010-05-01
    Company Name: Dendreon
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing